The advent of tyrosine kinase inhibitors (TKIs) that target BCR-ABL1 has dramatically changed the Philadelphia chromosome-positive (Ph+) CML therapeutic landscape (4). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.